Topomer-CoMFA Study of Tricyclic Azepine Derivatives-EGFR Inhibitors

  • Chung, Jae-Yoon (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) ;
  • Pasha, F.A. (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) ;
  • Chung, Hwan-Won (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) ;
  • Yang, Beom-Seok (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) ;
  • Lee, Cheol-Ju (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) ;
  • Oh, Jung-Soo (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) ;
  • Moon, Myoung-Woon (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) ;
  • Cho, Seung-Joo (Computational Science Center, Future Fusion Technology Division, Korea Institute of Science and Technology) ;
  • Cho, Art E. (Department of Biotechnology and Bioinformatics, Korea University)
  • Published : 2008.03.31

Abstract

EGFR has been intensively investigated as a target to block the signal transduction pathway which stimulates cancer growth and metastasis. Studies about structure-activity relationship for tricyclic azepine derivatives were performed with topomer-CoMFA. The derived topomer-CoMFA model with steric and electrostatic field parameters based on fragment units gave reasonable statistics ($q^2$=0.561, $r^2$=0.679). The model explains why a halogen atom at the meta position of aniline is important to increases inhibitory activity. This comes from an electrostatically negative groups are favored near this region. The model also shows that there are sterically favored regions around methoxy group extended from oxazepine derivatives. The findings about steric and electrostatic effects can be utilized for designing new inhibitors.

Keywords

References

  1. Kurup, A., Garg, R. & Hansch, C. Comparative QSAR study of tyrosine kinase inhibitors. Chem Rev 101:2573-2600 (2001) https://doi.org/10.1021/cr010154c
  2. Sorrentino, B. P. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat Rev Cancer 2:431-441 (2002) https://doi.org/10.1038/nrc823
  3. Katsman, A., Umezawa, K. & Bonavida, B. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. Drug Resistance Updates 10:1-12 (2007) https://doi.org/10.1016/j.drup.2007.01.002
  4. Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nature Reviews Drug Discovery 1:309-315 (2002) https://doi.org/10.1038/nrd773
  5. Hubbard, S. R. & Till, J. H. Protein tyrosine kinase structure and function. Annual Review of Biochemistry 69:373-398 (2000) https://doi.org/10.1146/annurev.biochem.69.1.373
  6. Lo, H-W., Hsu, S. C. & Hung, M. C. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Research and Treatment 95:211-218 (2006) https://doi.org/10.1007/s10549-005-9011-0
  7. Janmaat, M. L. & Giaccone, G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 8:576-586 (2003) https://doi.org/10.1634/theoncologist.8-6-576
  8. Toschi, L. & Cappuzzo, F. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 12:211-220 (2007) https://doi.org/10.1634/theoncologist.12-2-211
  9. Noble, M. E. M., Endicott, J. A. & Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Sience 303:1800-1805 (2004) https://doi.org/10.1126/science.1095920
  10. Dawson, J. P. et al. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 25:7734-7742 (2005) https://doi.org/10.1128/MCB.25.17.7734-7742.2005
  11. Baselga, J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7:2-8 (2002)
  12. Traxler, P. et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Medicinal Research Reviews 21:499-512 (2001) https://doi.org/10.1002/med.1022
  13. Stamos, J., Sliwkowski, M. X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277:46265-46272 (2002) https://doi.org/10.1074/jbc.M207135200
  14. Smith Ii, L. et al. Novel tricyclic azepine derivatives: biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters 16:5102-5106 (2006) https://doi.org/10.1016/j.bmcl.2006.07.031
  15. Bridges, A. J. et al. Tyrosine kinase inhibitors. 8. an unusually steep structure-activity relationship for analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem 39:267-276 (1996) https://doi.org/10.1021/jm9503613
  16. Cramer, R. D. Topomer CoMFA: A design methodology for rapid lead optimization. J Med Chem 46:374-388 (2003) https://doi.org/10.1021/jm020194o
  17. Jilek, R. J. & Cramer, R. D. Topomers: a validated protocol for their self-consistent generation. J Chem Inf Comput Sci 44:1221-1227 (2004) https://doi.org/10.1021/ci049961d
  18. Cramer, R. D. & Jilek, R. J. Comparative field analysis (CoMFA) utilizing topomeric alignment of molecular fragments. United States. (2003)
  19. Cramer, R. D. & Patterson, D. E. Further method of creating and rapidly searching a virtual library of potential molecules using validated molecular structural descriptors. United States. (2001)
  20. Tripos Bookshelf 7.3. Tripos Inc. (1699)
  21. Bush, B. L. & Nachbar, R. B. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. Journal of Computer-Aided Molecular Design 7:587-619 (1993) https://doi.org/10.1007/BF00124364
  22. Wold, S., Sjostrom, M. & Eriksson, L. PLS-regression: a basic tool of chemometrics. Chemometrics and Intelligent Laboratory Systems 58:109-130 (2001) https://doi.org/10.1016/S0169-7439(01)00155-1